Table 4.
Cumulative incidences of aGVHD III–IV and GVHD-associated NRM according to ATG prophylaxis.
| Clinical Endpoint | Entire Cohort n = 775 | C1/1 n = 291 | C1/2 n = 363 | C2/2 n = 121 |
|---|---|---|---|---|
| aGVHD III–IV (12 mo) | 27.1 (23.2–31.7) | 30.6 (24.2–38.6) | 26.4 (20.9–33.4) | 21.1 (13.5–33.1) |
| without ATG (%) | n = 425 | n = 161 | n = 193 | n = 71 |
| aGVHD III–IV (12 mo) | 21.9 (18.0–26.7) | 21.1 (15.1–29.5) | 23.0 (17.5–30.3) | 20.4 (11.8–35.5) |
| with ATG (%) | n = 350 | n = 130 | n = 170 | n = 50 |
| ATG effect by multivariate | RR, 0.63 | RR, 0.44 | RR, 0.77 | RR, 0.49 |
| analysis | p = 0.02 | p = 0.01 | p = 0.35 | p = 0.28 |
| GVHD-ass. NRM * (24 mo) | 24.9 (21.1–29.4) | 28.1 (21.9–36.0) | 23.5 (18.2–30.4) | 21.2 (13.6–33.3) |
| without ATG (%) | n = 425 | n = 161 | n = 193 | n = 71 |
| GVHD-ass. NRM (24 mo) | 20.5 (16.6–25.3) | 18.4 (12.5–26.9) | 21.2 (15.8–28.5) | 24.1 (14.7–39.5) |
| with ATG (%) | n = 350 | n = 130 | n = 170 | n = 50 |
| ATG effect by multivariate | RR, 0.51 | RR, 0.28 | RR, 0.55 | RR, 1.34 |
| analysis | p = 0.001 | p = 0.0002 | p = 0.04 | p = 0.6 |
* Defined as any non-relapse mortality within 24 months after transplant in a patient with active or previous aGVHD requiring systemic treatment (i.e., grade 2–4).